scholarly journals Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study

2008 ◽  
Vol 58 (10) ◽  
pp. 2968-2980 ◽  
Author(s):  
Mark C. Genovese ◽  
James D. McKay ◽  
Evgeny L. Nasonov ◽  
Eduardo F. Mysler ◽  
Nilzio A. da Silva ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Drug Therapy ◽  
Inadequate Response ◽  
Disease Modifying Antirheumatic Drugs ◽  
Antirheumatic Drugs ◽  
Receptor Inhibition ◽  
Interleukin 6 Receptor ◽  
Disease Modifying ◽  
Antirheumatic Drug Therapy ◽  
Disease Modifying Antirheumatic Drug

High Degree of Nonadherence to Disease-modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis

2015 ◽  
Vol 42 (3) ◽  
pp. 386-390 ◽  
Author(s):  
Veronika Rauscher ◽  
Matthias Englbrecht ◽  
Désirée van der Heijde ◽  
Georg Schett ◽  
Axel J. Hueber
Keyword(s):  
Rheumatoid Arthritis ◽  
Drug Therapy ◽  
Full Information ◽  
Disease Modifying Antirheumatic Drugs ◽  
Antirheumatic Drugs ◽  
Cutoff Scores ◽  
Disease Modifying ◽  
High Degree ◽  
Antirheumatic Drug Therapy ◽  
Test Medication

Objective.To test medication adherence using the Compliance-Questionnaire-Rheumatology (CQR).Methods.Invitation letter and CQR were sent to 240 patients with rheumatoid arthritis. Followup CQR was sent 3 months later. Adherence was evaluated using CQR 80% cutoff scores.Results.Seventy-eight patients who were being treated with disease-modifying antirheumatic drugs provided full information on the CQR at both points in time. Eleven patients (14.1%) were classified as adherent based on taking compliance (TC), with only 3 patients (3.8%) adherent in regard to correct dosing (CD) [followup: 13 (16.7%) and 3 (3.8%) for TC and CD, respectively]. Nonadherence was not related to disease activity or side effects.Conclusion.We demonstrated low adherence, suggesting differences between doctors’ records and patients’ practice of antirheumatic drug therapy.

scholarly journals Hepatitis B Screening Before Biologic or Targeted Synthetic Disease-modifying Antirheumatic Drug Therapy: Many Roads to Improvement

2021 ◽  
pp. jrheum.211000
Author(s):  
Alfredo Aguirre ◽  
Jinoos Yazdany
Keyword(s):  
Drug Therapy ◽  
Hepatitis B ◽  
Hbv Reactivation ◽  
Disease Modifying Antirheumatic Drugs ◽  
Antirheumatic Drugs ◽  
B Virus ◽  
Disease Modifying ◽  
Hepatitis B Screening ◽  
Antirheumatic Drug Therapy ◽  
Disease Modifying Antirheumatic Drug

Biologic and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) have long been recognized to cause hepatitis B virus (HBV) reactivation in individuals chronically infected with or previously exposed to HBV.1 Despite this knowledge, many patients treated with b/tsDMARDs experience HBV reactivation each year because of inconsistent screening.2

scholarly journals Tofacitinib 5 mg Twice Daily in Patients with Rheumatoid Arthritis and Inadequate Response to Disease-Modifying Antirheumatic Drugs

2019 ◽  
Vol 25 (3) ◽  
pp. 115-126 ◽  
Author(s):  
Paul Bird ◽  
William Bensen ◽  
Bassel El-Zorkany ◽  
Jeffrey Kaine ◽  
Bernadette Heizel Manapat-Reyes ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Inadequate Response ◽  
Disease Modifying Antirheumatic Drugs ◽  
Antirheumatic Drugs ◽  
Disease Modifying
Sign in / Sign up

Export Citation Format

Share Document